Effects of Switching from Efavirenz to Raltegravir on Endothelial Function, Bone Mineral Metabolism, Inflammation, and Renal Function: a Randomized, Controlled Trial

Overview

Journal J Acquir Immune Defic Syndr

Specialty Infectious Diseases

Date 2013 Nov 27

PMID 24278992

Citations 25

Authors

Samir K Gupta

Deming Mi

Sharon M Moe

Michael P Dube

Ziyue Liu

Affiliations

Soon will be listed here.

Abstract

We performed a randomized controlled trial in 30 HIV-infected participants to either continue tenofovir/emtricitabine/efavirenz (Continuation Group) or switch to tenofovir/emtricitabine/raltegravir (Switch Group) for 24 weeks. There were no significant differences in the changes in flow-mediated dilation, 25(OH) vitamin D, or parathyroid hormone levels. Total cholesterol, high sensitivity C-reactive protein, serum alkaline phosphatase, sCD14 levels, and renal function significantly declined in the Switch Group compared with the Continuation Group; however, sCD163 levels significantly increased in the Switch Group. These findings suggest that raltegravir is not inherently more beneficial to endothelial function compared with efavirenz but may impact renal function and monocyte activation.

Citing Articles

A systematic review assessing the association of inflammatory markers with kidney dysfunction in people living with HIV on highly active antiretroviral therapy.

Choshi J, Hanser S, Mabhida S, Mokoena H, Moetlediwa M, Muvhulawa N BMC Infect Dis. 2024; 24(1):776.

PMID: 39095687 PMC: 11297709. DOI: 10.1186/s12879-024-09594-5.

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks.

Mulindwa F, Schwarz J, Brusselaers N, Nabwana M, Bollinger R, Buzibye A BMC Infect Dis. 2024; 24(1):746.

PMID: 39075383 PMC: 11285129. DOI: 10.1186/s12879-024-09655-9.

Risk Compensation After Initiation of Daily Oral Pre-exposure Prophylaxis Among Sexual and Gender Minorities in Nigeria.

Adeyemi O, Nowak R, Morgan D, Sam-Agudu N, Craddock J, Zhan M Arch Sex Behav. 2024; 53(7):2807-2816.

PMID: 38684621 PMC: 11758484. DOI: 10.1007/s10508-024-02859-9.

HIV Infection, Antiretroviral Drugs, and the Vascular Endothelium.

Kanmogne G Cells. 2024; 13(8.

PMID: 38667287 PMC: 11048826. DOI: 10.3390/cells13080672.

The changing landscape of HIV-associated kidney disease.

Diana N, Naicker S Nat Rev Nephrol. 2024; 20(5):330-346.

PMID: 38273026 DOI: 10.1038/s41581-023-00801-1.

References

Friis-Moller N, Reiss P, Sabin C, Weber R, Monforte A, El-Sadr W . Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007; 356(17):1723-35. DOI: 10.1056/NEJMoa062744. View

Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiba T . A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2012; 75(4):990-6. PMC: 3612717. DOI: 10.1111/j.1365-2125.2012.04440.x. View

Corretti M, Anderson T, Benjamin E, Celermajer D, Charbonneau F, Creager M . Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002; 39(2):257-65. DOI: 10.1016/s0735-1097(01)01746-6. View

Patterson K, Prince H, Stevens T, Shaheen N, Dellon E, Madanick R . Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS. 2013; 27(9):1413-9. PMC: 4016763. DOI: 10.1097/QAD.0b013e32835f2b49. View

Lennox J, DeJesus E, Lazzarin A, Pollard R, Madruga J, Berger D . Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009; 374(9692):796-806. DOI: 10.1016/S0140-6736(09)60918-1. View

Inker L, Schmid C, Tighiouart H, Eckfeldt J, Feldman H, Greene T . Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012; 367(1):20-9. PMC: 4398023. DOI: 10.1056/NEJMoa1114248. View

Barenbrock M, Hausberg M, Kosch M, Kisters K, Hoeks A, Rahn K . Effect of hyperparathyroidism on arterial distensibility in renal transplant recipients. Kidney Int. 1998; 54(1):210-5. DOI: 10.1046/j.1523-1755.1998.00963.x. View

Cockcroft D, GAULT M . Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. DOI: 10.1159/000180580. View

Masia M, Martinez E, Padilla S, Gatell J, Gutierrez F . Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study. J Antimicrob Chemother. 2012; 68(2):409-13. DOI: 10.1093/jac/dks412. View

10.

Kathiresan S, Gona P, Larson M, Vita J, Mitchell G, Tofler G . Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation. 2006; 113(7):938-45. DOI: 10.1161/CIRCULATIONAHA.105.580233. View

11.

Sackoff J, Hanna D, Pfeiffer M, Torian L . Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006; 145(6):397-406. DOI: 10.7326/0003-4819-145-6-200609190-00003. View

12.

Jolma P, Koobi P, Kalliovalkama J, Saha H, Fan M, Jokihaara J . Treatment of secondary hyperparathyroidism by high calcium diet is associated with enhanced resistance artery relaxation in experimental renal failure. Nephrol Dial Transplant. 2003; 18(12):2560-9. DOI: 10.1093/ndt/gfg374. View

13.

Sandler N, Wand H, Roque A, Law M, Nason M, Nixon D . Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011; 203(6):780-90. PMC: 3071127. DOI: 10.1093/infdis/jiq118. View

14.

Daar E, Tierney C, Fischl M, Sax P, Mollan K, Budhathoki C . Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011; 154(7):445-56. PMC: 3430716. DOI: 10.7326/0003-4819-154-7-201104050-00316. View

15.

Gupta S, Shen C, Moe S, Kamendulis L, Goldman M, Dube M . Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PLoS One. 2012; 7(9):e45716. PMC: 3447812. DOI: 10.1371/journal.pone.0045716. View

16.

Hatano H, Scherzer R, Wu Y, Harvill K, Maka K, Hoh R . A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection. J Acquir Immune Defic Syndr. 2012; 61(3):317-25. PMC: 3480968. DOI: 10.1097/QAI.0b013e31826e7d0f. View

17.

Burdo T, Lo J, Abbara S, Wei J, DeLelys M, Preffer F . Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011; 204(8):1227-36. PMC: 3203384. DOI: 10.1093/infdis/jir520. View

18.

Baykan M, Erem C, Erdogan T, Hacihasanoglu A, Gedikli O, Kiris A . Impairment of flow mediated vasodilatation of brachial artery in patients with primary hyperparathyroidism. Int J Cardiovasc Imaging. 2006; 23(3):323-8. DOI: 10.1007/s10554-006-9166-8. View

19.

Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C . Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008; 197(1):102-8. DOI: 10.1086/524061. View

20.

Lake J, McComsey G, Hulgan T, Wanke C, Mangili A, Walmsley S . A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS. 2012; 26(9):532-40. PMC: 3426192. DOI: 10.1089/apc.2012.0135. View